Results 151 to 160 of about 224,807 (304)
Multipathway schematic of endocrine therapy–induced cancer‐related fatigue. Endocrine interventions trigger four interacting mechanisms—neuroendocrine dysregulation, systemic inflammation, energy‐metabolic failure, and psycho‐behavioral amplification—that culminate in the multidimensional CRF phenotype.
Jiajing Jiang +7 more
wiley +1 more source
ABSTRACT Background A higher ratio of IGF‐1:IGF binding protein 1 (IGFBP1) was associated with improved prognosis in the CHAARTED trial of docetaxel in participants with metastatic hormone‐sensitive prostate cancer (mHSPC). The ENZAMET trial demonstrated the survival benefit of adding enzalutamide to androgen deprivation therapy (ADT) in mHSPC, and ...
Michael A. Cilento +15 more
wiley +1 more source
Economical impact of orchiectomy for advanced prostate cancer
PURPOSE: To demonstrate the economical impact of surgical castration in comparison to the medical castration for patients with advanced prostate cancer.
Paula Adriano A. P. de +6 more
doaj
ABSTRACT Background Androgen receptor pathway inhibitors (ARPIs) such as abiraterone and enzalutamide are common therapies in the management of metastatic castration‐resistant prostate cancer (mCRPC). However, the comparative effectiveness of these oral ARPIs in frail and comorbid patient populations remains uncertain.
Meghana Yellanki +6 more
wiley +1 more source
Human Prostate Cell Lines: Derivation, Molecular Characteristics and Appropriate Use
ABSTRACT Background Research on prostate cancer and benign prostatic hyperplasia depends on a small number of immortalized human cell lines established between 1977 and 2001, most of them from advanced metastatic disease. The cell lines differ from one another in androgen receptor status, prostate‐specific antigen secretion, p53 status, karyotype and ...
Hamza Abohamra, Keenau Mark Pearce
wiley +1 more source
ABSTRACT Background The prognostic significance of time to metastasis (TTM) following radical prostatectomy in patients with metachronous metastatic hormone‐sensitive prostate cancer (mHSPC) remains uncertain. We performed a secondary analysis of patient‐level data from the phase 3 SWOG 1216 randomized clinical trial to evaluate whether TTM is ...
Nicolas Sayegh +15 more
wiley +1 more source
ABSTRACT Background Chronic exposure to androgen receptor (AR)‐targeted therapies can drive lineage plasticity, leading to treatment resistance and neuroendocrine prostate cancer (NEPC), characterized by loss of AR expression and acquisition of neuroendocrine (NE) markers including synaptophysin (SYP). We evaluated concordance between circulating tumor
Ethan Lo +16 more
wiley +1 more source
The interplay between molecular architecture, pharmacology, and suspected adverse drug reactions associated with nonsteroidal androgen antagonists in the United Kingdom. [PDF]
Dhillon S, Antolin AA, Jones AM.
europepmc +1 more source
ABSTRACT Background Circulating steroid trajectories after robot‐assisted radical prostatectomy are poorly characterized from the day‐of‐surgery baseline, and relevant biology extends beyond testosterone and dihydrotestosterone to adrenal‐derived 11‐oxygenated androgens and steroid conjugate turnover.
Jiri Heracek +8 more
wiley +1 more source

